CA-XSOLLA
14.3.2024 15:22:26 CET | Business Wire | Press release
Xsolla, a global video game commerce company, announces its partnership with GameAnalytics, a premier analytics platform in the gaming industry. This partnership marks the beginning of a new era of in-game monetization, with the integration of Xsolla's Web Shop into the GameAnalytics platform. The initiative aims to provide game developers with next-generation tools for direct-to-consumer sales, starting with a pioneering proof of concept centered around the Xsolla Web Shop.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314598476/en/
(Graphic: Xsolla)
"This partnership with GameAnalytics is a game-changer for developers worldwide. Combining GameAnalytics' powerful data analysis tools with Xsolla's comprehensive sales solutions provides developers with an unprecedented opportunity to understand and engage their audience directly," said Berkley Egenes, Chief Marketing Officer and Chief Growth Officer at Xsolla. "This empowers developers to maximize their revenue potential and enhances the gaming experience for players by ensuring the games they love continue to thrive."
Game developers integrate their games with GameAnalytics to access mission-critical data and uncover valuable insights about their games’ performance, including engagement and monetization data. This, above others, allows them to understand player spending behavior, optimize their revenue streams, and maximize earning potential.
"We are excited to embark on this partnership with Xsolla, a company that shares our commitment to empowering game developers," said Allison Bilas, COO at GameAnalytics. “Integrating Xsolla's Web Shop into our analytics platform opens new avenues for developers to monetize their games more effectively. This collaboration is about providing actionable insights that enable developers to craft compelling experiences for gamers while optimizing their revenue streams. It's a testament to our shared vision of supporting the growth and success of the gaming community."
Xsolla is a pivotal player in the gaming industry, collaborating with thousands of developers, publishers, and platforms, including Epic Games, Roblox, Twitch, Steam, Kabam, Niantic, EA, Warner Brothers, Wizards of the Coast, Sega, Take Two, SciPlay and Miniclip. As a merchant of record, Xsolla undertakes the risk and operational complexity associated with direct-to-consumer video game sales, addressing challenges such as chargebacks, fraud, taxes, and compliance laws. This partnership underscores Xsolla's commitment to supporting the gaming community by facilitating direct sales to consumers online, bypassing substantial platform fees associated with traditional app stores.
With the recent announcement of powering web shops for 40 of the top 100 mobile games, Xsolla continues demonstrating its dedication to innovation and support for mobile game developers. The collaboration with GameAnalytics represents a significant step forward in achieving this goal, offering developers cutting-edge tools to analyze, understand, and monetize their games effectively.
For more information about the partnership, please visit: https://xsolla.pro/xsolla-gameanalytics
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
About GameAnalytics
GameAnalytics is the leading analytics solution for indie developers, game studios, and powerhouse publishers globally. Their network covers 100,000 games played by over 1.75 billion people for an average of 24 billion monthly sessions. The GameAnalytics platform enables game development teams to rapidly refine gameplay, improve retention, and increase revenue with real-time data analysis for all major game engines and operating systems through simple SDK integration. GameAnalytics was founded in 2012 by Danish serial entrepreneur Morten E. Wulff, who remains the company's Chairman today. After raising over $8M in funding, the leading mobile advertising company, Mobvista, acquired the company in 2016. To learn more and get started for free, visit gameanalytics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314598476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom